Move ahead of the curve. Here’s a simple plan: shift your focus from broad markets to key sectors to find the real opportunities that America’s roaring markets offer.
Here’s where to look now for wealth-building investment strategies:
Many will tell you that little or no upside room remains in the Dow or S&P. In fact, these popular indices may be staged for a sharp, costly correction. Flirting with such record highs, these are likely not the places to look when seeking to build your personal wealth. You simply can’t expect mature companies, like those on the big boards, to maximize opportunities. Instead, you could go deep to find the companies that can pay multi-fold profits.
So, drill deeper. Target the top performing sectors. Seek innovative companies developing new technologies poised to reward early shareholders with enormous gains. It’s that simple and it’s a formula that has produced big returns again and again.
Among the top performers at this point in time is the medical device sector. Over the last five years, this one sector has outperformed the S&P 500 by more than double. Over the last six months, by more than triple!
Huge upside in the near- and long-term without the risk of pharmaceuticals.
Medical device technologies have made fortunes for investors who caught innovators early in the product development stages. Explosive gains can come quickly as these small-cap companies leap on stage with true innovation.
It’s an ideal sector to search out a rising star. Medical devices can pay big returns similar to a successful pharmaceutical innovation. But unlike the pharmaceutical sector, medical device innovation is not burdened by the same staggering R&D expense and lengthy approvals process.
In fact, the medical device space is the one sector where you can hunt for big rewards in medicine with less of the downside risk that a last minute denial from the FDA poses to all big pharmaceuticals.
Within the medical device sector, lower R&D costs make it possible for small companies to make enormous health care breakthroughs. And once proven effective, the resulting intellectual property can be worth hundreds of millions.
Quick profits as well as long term wealth-building.
Consider the history of Inogen (INGN). Inogen introduced the first truly portable oxygen concentrator to market in 2013. Over the last five years since its introduction, INGN shares soared over 16-fold. $10,000 in INGN shares bought in 2013 would now be worth over $164,000.
And it continues to soar. Over the last six months, INGN shares have more than doubled. That’s an impressive return in a sector that has gone largely unnoticed.
Real breakthroughs; staggering share price gains.
Companies with maturing products, like Inogen, may still have some upside potential, but more than likely, INGN’s big gains are already built in. A great story, but not one you can follow for building wealth.
So focus on the future, not the past.
It’s not always to peer into the future of a market or product and that prevents many people from acting. What you should be looking for is a clear breakthrough, one that changes the landscape and offers a unique approach to a market niche in real need.
One emerging company that keeps coming up on the radar with all of these criteria is Imagin Medical (OTC: IMEXF / CSE: IME).
Imagin Medical is now progressing through advanced-stage development of technology that can revolutionize treatment of bladder cancer.
Yes, bladder cancer poses huge medical challenges burdened with decades-old technologies.
Start with the grim reality…
Not only is bladder cancer the fourth most common form of cancer in men… it’s also the most likely to re-occur. If not caught and treated in time, bladder cancer can progress to other parts of the body. This greatly complicates cancer treatment and often leads to fatal outcomes.
Also complicating the treatment process is the technology currently used to identify tumor locations. It literally dates back decades.
A 2009 report from the World Urology Journal released through the National Institute of Health (NIH) confirms the human and financial tolls of bladder cancer:
bladder cancer (bc) has the highest lifetime treatment costs per patient of all cancers.the high recurrence rate and ongoing invasive monitoring requirements are the key contributors to the economic and human toll of this disease. [author’s emphasis]
That said, bladder cancer does not hand down a certain death sentence.
With effective intervention bladder cancer survival rates can be quite high. When diagnosed early, surgical interventions are used to remove cancerous tissue. What’s more, surgery can be successful with minimally invasive procedures, sometimes even on an outpatient basis in a urologist’s clinic.
But here’s where it gets problematic. Bladder tumors can be removed successfully, but only if the surgeon can actually see where the cancer is located. If the surgeon misses some tumorous tissue, it’s not because they didn’t do their job…it’s because the tumor could not be seen. The visualization problems make recurrence of cancerous growths almost inevitable.
The American Urological Society states it plainly: “Incomplete [tumor] removal is likely a significant contributing factor to early bladder cancer recurrences.”
So, don’t blame the surgeon. This is about limitations of available technology. Current visualization tools make the surgeon’s job very challenging. Even a few cancerous cells left behind means the cancer can take hold again.
Here’s where Imagin Medical can have a dramatic impact. Its i/Blue Imaging System offers surgeons a new advanced technology that simplifies and improves accuracy, highlighting bladder cancer tumors for surgical removal. Chances for complete tumor removal are greatly improved and the incidence of cancer recurrence is reduced.
This is a staggering breakthrough that carries enormous financial implications.
As of now, the company reports that it has completed development of an alpha prototype for its i/Blue imaging technology. In other words, the early R&D is done. Imagin Medical appears to be entering the home stretch… and this presents an ideal opportunity for those looking to get in on Imagin Medical in the early stages.
Once released to market, the i/Blue system can be expected to spread rapidly. Clearly, the bladder cancer market is in real need of this promising technology.
Based on product development phases and market conditions, this could be the ideal time to act on Imagin Medical (IMEXF). Imagin Medical has a way to go before it begins monetizing its technology.
However, there’s no risk in next steps.
First and foremost: put IMEXF on your watch list now, before this window of opportunity closes.
There seems little question that an enormous unmet, substantial need exists for Imagin’s i/Blue technology. This already existing vacuum of demand could quickly propel the i/Bluesystem to millions in sales. It may also trigger one event that investors look for in this scenario: a buyout by big med device or technology firms.
Imagin’s i/Blue cancer visualization technology is an ideal candidate for intellectual property rights acquisition. A major player operating in the medical device sector could soon pay enormous premiums to shareholders holding ground floor positions. At its current stage of product development, Imagin Medical appears well positioned.
For now, Imagin Medical remains virtually unknown in the medical device sector. However, don’t expect that to last: over the last few months, volume has been accelerating and word is beginning to get out. Today’s ground floor opportunity could vanish overnight following a single news release.
Many investors carefully follow companies like Imagin Medical, prepared to respond instantly on breakthrough news. Their rush to buy can trigger dramatic gains at a moment’s notice.
A single announcement can set off a stampede of buying from investors seeking last-minute shots at an early position. It’s tough to know when such an announcement may come, but one thing seems certain, Imagin Medical appears to be standing on the threshold of that event.
Take a moment right now to go to the Imagin Medical website and subscribe to their email list.
Go to: https://imaginmedical.com
While you’re on the site, take some time to begin your due diligence. You’ll find detailed explanations about bladder cancer, its treatment, and how i/Blue technology plans to revolutionize surgical interventions and dramatically improve the prognosis for bladder cancer patients.
An enormous market on standby for a new, effective solution!
Urology Times reports that the U.S. Department of Health and Human Services projects the need for 16,000 practicing urologists by the end of this decade. That’s a 37% leap over the 11,703 practicing urologists in 2014.
This projection likely recognizes that an aging male population will trigger a marked increase in bladder cancer diagnoses. This is the population most likely to contract the disease. The timing for Imagin Medical is likely ideal…as it is for the company’s shareholders.
Within a few years following a market release of the i/Blue system, you can look for significant penetration of the system into every hospital across the country. And hospitals aren’t the only market target. Also in the market for i/Blue are thousands of urology clinics where minimally invasive surgical procedures are routinely practiced these days.
In short order, you could see thousands of i/Blue systems sold and delivered…and that’s just in the United States.
The world market for the i/Blue system is likely to be many times the U.S. market alone. In Europe, 17,000 urologists are serving a population of 730 million today. Like America, the need for more is likely to increase sharply over the coming few years.
Imagin Medical is on a fast track
In July , the company announced that its i/Blue system was demonstrated in a ten-subject trial conducted at the University of Rochester Medical Center. This trial provided valuable feedback for further design enhancements to Imagin’s i/Blue technology.
Further, in parallel trials, the company announced successful completion of the critical “proof of concept” phase for its optical modules. This is a key phase of development prior to the creation of a functioning and final product designed for market.
For further details on these and other key company developments, visit the company website and be sure to register for their email list. If you have any interest in Imagin Medical, getting on the company’s email list is essential for ongoing due diligence.
Go to: https://imaginmedical.com
The assembled information disseminated by Financials Trend is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Financials Trend does expect that investors will buy and sell securities based on information assembled and presented in Financials Trend. PLEASE always do your own due diligence, and consult your financial advisor.
All assembled information within Financials Trend is subject to change without notice. The assembled information within Financials Trend is based on information supplied by the company, press releases, SEC filings, or from other sources believed to be reliable as of the date of the report on the featured companies, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. An affiliate of the Financials Trend is a registered investment advisor. Financials Trend and its affiliates and authors are not, brokers, broker-dealers, market makers, investment bankers, analysts or underwriters.
Forward Looking Statements
Information in our emails and on Financials Trend will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. An example of forward-looking information are statements relating to the future anticipated direction of the industry, plans for future expansion, various business development activities, planned capital expenditures, future funding sources, anticipated sales growth and potential contracts. These and similar forward statements are subject to a number of known and unknown risks and uncertainties outside our control that could cause actual operations or results to differ materially from those anticipated.
The cautionary statements made in this document should be read as being applicable to all related forward-looking statements wherever they appear on Financials Trend or in other communications.
We encourage you to visit the Securities Exchanges Commission Web site https://www.sec.gov and read about how to avoid Internet Scams and other valuable information.
In order to be in full compliance with the Securities Act of 1933, Section 17(b), Financials Trend and its management will fully disclose if they receive fees from profiled companies or agents representing the profiled companies. These fees may be paid in cash, securities of profiled companies, or both, and will be completely disclosed in each profile.
Since Financials Trend receives compensation from the companies that it profiles or other third party agencies and its employees, affiliates, or members of their families could hold stock in the profiled companies, there is an inherent conflict of interest in the statements and opinions, and such statements and opinions are not independent.